Mental and Behavioral Health Disorders MBHD Among Patients With Metastatic and Nonmetastatic Cancer: A Claims-Based Analysis
Author(s)
Ali Tafazzoli, PhD1, Yi Zhang, MPS2, Yen-Hua Chen, MA2, Anuraag Kansal, PhD1.
1GRAIL, Inc., Menlo Park, CA, USA, 2KMK Consulting, Inc., Morristown, NJ, USA.
1GRAIL, Inc., Menlo Park, CA, USA, 2KMK Consulting, Inc., Morristown, NJ, USA.
OBJECTIVES: Cancer diagnosis and treatment often bring a substantial burden on patients, significantly diminishing their quality of life. The mental component of this burden can present as MBHD such as anxiety, depression, stress, substance abuse, and somatoform disorders. This study explores the prevalence of MBHD in patients with metastatic vs non-metastatic cancers.
METHODS: A retrospective claims analysis was conducted using the IQVIA PharMetrics Plus dataset for patients newly diagnosed with metastatic and non-metastatic cancers in 2022. We examined the prevalence of MBHD claims within six months following cancer diagnosis, categorizing MBHDs using ICD-10-CM codes. Our analysis distinguished between first-onset and recurrent MBHDs by reviewing claims data one year prior to cancer diagnosis. Outcomes were stratified by cancer type, sex, and age group (50-64 and 65+ years).
RESULTS: Following a cancer diagnosis, MBHDs were experienced by 38% of women and 25% of men aged 50-64, and by 34% of women and 22% of men aged 65+. Of these, 36% of women and 46% of men experienced a first-onset MBHD post-cancer diagnosis; most commonly anxiety and depression. Patients with metastatic cancer at diagnosis had higher risk of first-onset MBHD compared to non-metastatic cancer: relative risk (95% CI) of 1.39 (1.22-1.59) for women and 2.00 (1.71-2.35) for men aged 50-64; 1.36 (1.25-1.47) for women and 1.71 (1.57-1.87) for men aged 65+. This elevated risk was observed across different cancer groupings, though with varying degrees. Risk of recurrent MBHDs was similar following metastatic and non-metastatic cancer diagnoses with relative risk of 1.00 (0.98-1.03).
CONCLUSIONS: The increased risk of first-onset MBHDs following metastatic cancer diagnoses relative to earlier diagnoses highlights the potential impact of early detection and intervention to reduce the mental health impact on quality of life in those diagnosed with cancer.
METHODS: A retrospective claims analysis was conducted using the IQVIA PharMetrics Plus dataset for patients newly diagnosed with metastatic and non-metastatic cancers in 2022. We examined the prevalence of MBHD claims within six months following cancer diagnosis, categorizing MBHDs using ICD-10-CM codes. Our analysis distinguished between first-onset and recurrent MBHDs by reviewing claims data one year prior to cancer diagnosis. Outcomes were stratified by cancer type, sex, and age group (50-64 and 65+ years).
RESULTS: Following a cancer diagnosis, MBHDs were experienced by 38% of women and 25% of men aged 50-64, and by 34% of women and 22% of men aged 65+. Of these, 36% of women and 46% of men experienced a first-onset MBHD post-cancer diagnosis; most commonly anxiety and depression. Patients with metastatic cancer at diagnosis had higher risk of first-onset MBHD compared to non-metastatic cancer: relative risk (95% CI) of 1.39 (1.22-1.59) for women and 2.00 (1.71-2.35) for men aged 50-64; 1.36 (1.25-1.47) for women and 1.71 (1.57-1.87) for men aged 65+. This elevated risk was observed across different cancer groupings, though with varying degrees. Risk of recurrent MBHDs was similar following metastatic and non-metastatic cancer diagnoses with relative risk of 1.00 (0.98-1.03).
CONCLUSIONS: The increased risk of first-onset MBHDs following metastatic cancer diagnoses relative to earlier diagnoses highlights the potential impact of early detection and intervention to reduce the mental health impact on quality of life in those diagnosed with cancer.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
PCR159
Topic
Economic Evaluation, Patient-Centered Research, Real World Data & Information Systems
Topic Subcategory
Health State Utilities, Patient-reported Outcomes & Quality of Life Outcomes
Disease
No Additional Disease & Conditions/Specialized Treatment Areas, Oncology